---
title: "HIMS Earnings: Hims & Hers Stock Falls 10% as Financial Results Miss Wall Street Targets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285994588.md"
description: "Hims & Hers Health (HIMS) saw its stock drop 10% in after-hours trading after reporting Q1 revenue of $608 million, missing the $616.8 million estimate. The company also posted a loss per share of -$0.40, while analysts expected a profit of $0.03. Despite lowering its revenue guidance to $2.8-$3 billion, Wall Street had anticipated $2.7 billion. The company is under scrutiny following a legal issue with Novo Nordisk over a weight-loss pill. HIMS has a consensus Moderate Buy rating among analysts, with an average price target of $28.02, indicating a potential 4% downside."
datetime: "2026-05-11T20:31:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285994588.md)
  - [en](https://longbridge.com/en/news/285994588.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285994588.md)
---

# HIMS Earnings: Hims & Hers Stock Falls 10% as Financial Results Miss Wall Street Targets

The stock of Hims & Hers Health (HIMS) fell as much as 10% in after-hours trading as the telehealth company reported financial results that missed Wall Street targets across the board.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

For the year's first quarter, the company reported $608 million in revenue, which was below the $616.8 million consensus estimate of analysts. Hims & Hers also announced a loss per share of -$0.40, compared to an expected profit of $0.03.

Looking ahead, management at the company said that they expect revenue between $2.8 billion and $3 billion, compared to previous guidance that called for sales of $2.7 billion to $2.9 billion. Wall Street had $2.7 billion penciled in for Hims & Hers.

## **Drama at Hims & Hers**

The poor financial results come during a period of high dramatic at the company. In February of this year, Hims & Hers rolled out a copy of Novo Nordisk's (NVO) Wegovy weight-loss pill, which it eventually pulled after getting sued by the drug maker.

The incident led to increased scrutiny of Hims & Hers by regulators. Today, the company partners with Novo Nordisk on the distribution of branded GLP-1 weight-loss drugs in exchange for dropping its cheaper, higher-margin knock-off medications.

## **Is HIMS Stock a Buy?**

Hims & Hers stock has a consensus Moderate Buy rating among 15 Wall Street analysts. That rating is based on five Buy and 10 Hold recommendations issued in the last three months. The average HIMS price target of $28.02 implies 4% downside from current levels. These ratings could change after the company's financial results.

### Related Stocks

- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Is Hims and Hers Health stock a buy after its latest dip?](https://longbridge.com/en/news/286450228.md)
- [Why Hims & Hers Health stock just crashed](https://longbridge.com/en/news/286133577.md)
- [BUZZ-Hims & Hers Health shares stabilize after boosted $350 mln convertible deal](https://longbridge.com/en/news/286896810.md)
- [Hims prices $350M 0.00% convertible notes due 2032, upsized from $300M](https://longbridge.com/en/news/286911997.md)
- [Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?](https://longbridge.com/en/news/286135059.md)